Immune checkpoint blockers (ICBs) therapy stands as the first‐line treatment option for advanced renal cell carcinoma (RCC). However, its effectiveness is hindered by the immunosuppressive tumor microenvironment (TME). Sonodynamic therapy (SDT) generates tumor cell fragments that can prime the host's antitumor immunity. Nevertheless, the hypoxic microenvironment and upregulated autophagy following SDT often lead to cancer cell resistance. In response to these challenges, a hypoxia‐responsive polymer (Poly(4,4′‐azobisbenzenemethanol‐PMDA)‐mPEG5k, P‐APm) encapsulating both a HIF‐2α inhibitor (belzutifan) and the ultrasonic sensitize (Chlorin e6, Ce6) is designed, to create the nanoparticle APm/Ce6/HIF. APm/Ce6/HIF combined with ultrasound (US) significantly suppresses tumor growth and activates antitumor immunity in vivo. Moreover, this treatment effectively transforms the immunosuppressive microenvironment from “immune‐cold” to “immune‐hot”, thereby enhancing the response to ICBs therapy. The findings indicate that APm/Ce6/HIF offers a synergistic approach combining targeted therapy with immunotherapy, providing new possibilities for treating RCC.
3 March 2023 in International Journal of Machine Learning and Cybernetics
Background Prostate cancer is one of the common malignant tumors in men. Recent studies have reported that non-invasive liquid biopsy is of great significance in tumor diagnosis. We hope to find relevant detection genes to establish a diagnostic and prognostic model for prostate cancer. Methods This study was based on the RNA expression data of prostate cancer patients from the The Cancer Genome Atlas (TCGA) database and the data of exosome-related genes from the GeneCards website. Key exosome-related differential genes were identified through cluster modeling, univariate and multivariate regression analyses. The roles of these genes in the occurrence and prognosis of prostate cancer were assessed using ROC curves and survival analysis. Validation was performed using prostate cancer patient data from the Gene Expression Omnibus (GEO) database. Results Firstly, we obtained 117 exosome-related differential genes (ERDEGs) from the RNA expression data of prostate cancer patients in the TCGA database. Next, through Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis, univariate Cox regression analysis, and multivariate Cox regression analysis of the ERDEGs, we obtained three genes that were significantly associated with prognosis (AQP2, H4C2, ZNF114) and calculated the risk score accordingly. Patients were divided into high-risk and low-risk groups based on this score, with significant differences in overall survival between the groups. At the same time, we conducted an immunological infiltration analysis on prostate cancer patients and Weighted correlation network analysis (WGCNA) on the ERDEGs. Finally, we used the GEO database (GSE69223, GSE229904) for verification and found that AQP2 and ZNF114 had good predictive value for the occurrence of prostate cancer. Conclusion Exosome-related genes such as AQP2 and ZNF114 exhibit good performance as non-invasive biomarkers in predicting the status and prognosis of prostate cancer to avoid the issues of high invasiveness associated with invasive examinations.
Background: The pivotal roles of long noncoding RNAs (lncRNAs) in the realm of cancer biology, inclusive of bladder cancer (BCa), have been substantiated through various studies. Remarkably, RNA methylation, especially m6A modification, has demonstrated its influence on both coding and noncoding RNAs. Nonetheless, the explicit impact of RNA methylation on lncRNAs and its subsequent contribution to the progression of BCa remains to be elucidated. Methods: In the present investigation, we scrutinized the expression and m6A methylation status of LINC01106, employing quantitative real-time PCR (qRT–PCR) and methylated RNA immunoprecipitation (MeRIP)-qPCR. To decipher the regulatory mechanism underpinning LINC01106, we utilized RNA immunoprecipitation (RIP)-qPCR, methylated RNA immunoprecipitation (MeRIP) assays, and bioinformatic analysis. Furthermore, the CRISPR/dCas13b-METTL3-METTL14 system was implemented to probe the function of LINC01106. Results: The findings of our study indicated that LINC01106 is under expressed and exhibits diminished m6A methylation levels in BCa tissues when compared those of normal controls. A diminished expression of LINC01106 was associated with a less favorable prognosis in BCa patients. Intriguingly, CRISPR-mediated hypermethylation of LINC01106, facilitated by dCas13b-M3-M14, abolished the malignant phenotype of the BCa cells, an effect that could be inverted by Disabled-1 (DAB1) knockdown. From a mechanistic standpoint, we identified an m6A modification site on LINC01106 and highlighted YTHDC1 as a potential reader protein implicated in this process. Additionally, a positive correlation between DAB1 and LINC01106 expression was observed, with miR-3148 potentially acting as a mediator in this relationship. Conclusions: In summary, our research unveils a suppressive regulatory role of the LINC01106/miR-3148/DAB1 axis in the progression of BCa and underscores the YTHDC1-mediated m6A modification mechanism in regards to LINC01106. These revelations propose a new therapeutic target for the management of BCa.
Background: Extramammary Paget’s disease (EMPD) is a rare cancer without standard therapy. We evaluated the safety and efficacy of a combination of the humanized monoclonal antiprogrammed death-1 (PD-1) antibody, carelizumab, with rivoceranib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients with advanced EMPD. Methods: This multicenter, single-arm, phase II trial included 12 patients with EMPD. The primary endpoint is the objective response rate (ORR), defined as the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 criteria. It is hypothesized that the ORR will be less than 10% if the treatment is ineffective and will reach 35% if effective. Secondary endpoints include progression-free survival (PFS) and safety assessments. Eligible patients are aged ≥18 years, with histologically confirmed advanced EMPD. Treatment consists of carelizumab (200 mg intravenously every 3 weeks) and rivoceranib (250 mg orally once daily), with dose adjustments permitted based on toxicity profiles. Results: Between June 2024 and February 2025, 12 patients were enrolled. One patient withdrew from the trial because of nontreatment-related accidents, and a total of 11 patients completed at least 1 cycle of treatment. The median PFS is 2.4 months (95% CI, 2.1-4.4 months). Among these 11 patients, no patients achieved CR or PR. Six patients (50%) experienced grade 3 adverse events. Conclusions: This is the first trial evaluating the combination of a PD-1 inhibitor and a VEGFR inhibitor in advanced EMPD. This combination therapy is well tolerated but does not appear to have clinically meaningful activity in advanced EMPD. This trial was registered at the Chinese Clinical Trial number registration: 2400086153.
Objective To identify DNA methylation markers related to clear cell renal cell carcinoma (ccRCC) prognosis and construct a prognostic model. Methods Methylation data from TCGA and GSE113501 dataset were analyzed. Differential analysis, univariate Cox regression, and LASSO regression were used to find survival—related CpG sites and build a risk score model. The model was evaluated by the area under the curve, and multivariate analysis determined risk factors. Results We determined 13 CpGs that are significantly associated with prognosis through a series of regression analyses and established a risk model based on them. Patients were divided into a high-risk group and a low-risk group according to the median risk score. The results showed that there was a significant difference in the overall survival rate between the two groups (p < 0.001), and the area under the curve (AUC) of the model was greater than 0.8. Verified by the GSE113501 dataset, the model performed well in distinguishing ccRCC with different progression states. In addition, by combining methylation data with gene expression analysis, five methylation-related differentially expressed genes (LINC02541, SLAMF8, LPXN, LGALS12, EGFR) were identified, and their expression levels were significantly upregulated in tumor tissues. Multivariate analysis indicated that age, clinical stage, and methylation risk score were independent prognostic factors. Conclusion This study confirmed that DNA methylation markers can effectively predict the progression and prognosis of clear cell renal cell carcinoma (ccRCC), providing a highly efficient and minimally invasive assessment tool for clinical practice.